Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round

X-COR’s innovative technology transforms support for patients with respiratory failure and includes COVID-19 treatment applications.

News
Published on:
November 20, 2020

FRAMINGHAM, MASSACHUSETTS – November 12, 2020 – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device for use in clinical trials. Alira Health’s investment arm, Alira Health Ventures, added X-COR Therapeutics in 2019 as a portfolio company and led the recent seed financing with syndication from Good Growth Capital, PiSA Biopharm, Flybridge Partners’ Graduate Syndicate, and other notable angel investors.

“X-COR Therapeutics is continuing to develop its novel filtration system and compatible dialysate strategy for clinical testing and regulatory assessment. Working with the Alira Health Ventures Team generated additional momentum for X-COR to advance development during the COVID-19 pandemic and the addition of Gabriele Brambilla to our board further accelerates our progress,” said Jayon Wang, CEO of X-COR.

“We are pleased with the X-COR Team’s progress through this unprecedented year and are proud to work with such an elite investor group supporting this important technology,” said Gabriele Brambilla, Alira Health’s CEO. “Alira Health Ventures is dedicated to nurturing innovative technologies and propelling development from concept to clinical evaluation for future commercialization. X-COR’s technology will be transformational in the lives of patients suffering from respiratory failure, and this funding is a key milestone in accelerating the development of this vital technology.”

About X-COR Therapeutics:

X-COR Therapeutics is a Boston-based medical device company creating the first commercially available carbon dioxide removal device that uses ultra-low-blood flows for a cheaper, safer, and more accessible treatment for acute respiratory failure. X-COR’s novel technology is a patent-pending medical device and accompanying control algorithm that enables physicians to directly remove excess carbon dioxide from lung failure patients.

About Alira Health Ventures:

As part of Alira Health, Alira Health Ventures is an accelerator for an innovative group of portfolio companies positioned to launch the next breakthrough technologies in medical devices and pharmaceuticals. From discovery to commercialization, Alira Health Ventures invests in products that advance healthcare and impact patients’ lives.

For more information about Alira Health Ventures

Click here

Related news

Publications January 19, 2023
Medical Device Regulation in 2023: A Window of Opportunity
We spoke with our team of regulatory experts about the recent news regarding the MDR and the opportunity it presents to device manufacturers in 2023.
Medical Devices MedTech Regulatory
Publications January 11, 2023
Regulatory Strategy for Registering Rare Disease Products in the EU: What You Need to Know
Given that the regulation is likely to change considerably, drug developers may need to revisit their development strategy. In the meantime, building a strategy around these evergreen(...)
EU Rare Disease Regulatory
Publications December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
Multimedia December 17, 2022
Webinar Replay: Partnering with Patients to Streamline Trial Operations: Protocol to Regulatory Submission in 60 days
Learn how patients and patient advocacy organizations can be directly enabled as powerful partners to facilitate all stages of DCT deployment, from protocol design, recruitment, engagement(...)
Clinical Trials Patient Centric Regulatory
Publications November 22, 2022
External Control Arms: The Way to Go?
The growing implementation of Single Arm Trials (SATs) with External Control Arms (ECAs) has been the subject of heated debate across Europe.
Clinical Trials Regulatory
Events October 7, 2022
Debate Sobre los IPT en Oncología
We are pleased to announce our next event, “Debate Sobre los IPT en Oncología,” focusing on price and reimbursement (P&R) of vital oncology and oncohematology therapies.
Market Access Product Development Regulatory
Events October 6, 2022
The MedTech Conference 2022
We are pleased to share that we will be joining the MedTech Conference 2022 as sponsors and speakers! This year’s edition will have more than 100 sessions focusing on today’s hot topics.
M&A MedTech Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.